Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications
Jacqueline Vuong, Ashley Stein-Merlob, Arash Nayeri, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 6, pp. 577-593
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Immune Checkpoint Inhibitor Therapy in Oncology
Sean Tan, Daphne Day, Stephen J. Nicholls, et al.
JACC CardioOncology (2022) Vol. 4, Iss. 5, pp. 579-597
Open Access | Times Cited: 96
Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure
Tamás G. Gergely, Zsófia D. Drobni, Marinos Kallikourdis, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 7, pp. 443-462
Closed Access | Times Cited: 16
Apolipoprotein B-containing lipoproteins in atherogenesis
Jan Borén, Chris J. Packard, Christoph J. Binder
Nature Reviews Cardiology (2025)
Closed Access | Times Cited: 2
A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)
Yan Lv, Xiao Ma, Yuxin Ma, et al.
Genes & Diseases (2022) Vol. 10, Iss. 6, pp. 2366-2382
Open Access | Times Cited: 68
Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors
Dorien Laenens, Yu‐Ling Yu, Béatrice Santens, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 29, pp. 3430-3438
Open Access | Times Cited: 67
Advances in Multimodality Imaging in Cardio-Oncology
Lauren A. Baldassarre, Sarju Ganatra, Juan Lopez‐Mattei, et al.
Journal of the American College of Cardiology (2022) Vol. 80, Iss. 16, pp. 1560-1578
Open Access | Times Cited: 58
Atherosclerosis With Immune Checkpoint Inhibitor Therapy
Giselle Alexandra Suero-Abreu, Markella V. Zanni, Tomas G. Neilan
JACC CardioOncology (2022) Vol. 4, Iss. 5, pp. 598-615
Open Access | Times Cited: 58
Novel Diagnostic Biomarkers Related to Oxidative Stress and Macrophage Ferroptosis in Atherosclerosis
Minhui Li, Siyuan Xin, Ruiyuan Gu, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-18
Open Access | Times Cited: 47
Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio‐Oncology
Carlo G. Tocchetti, Dimitrios Farmakis, Yvonne Koop, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 10, pp. 2055-2076
Closed Access | Times Cited: 15
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Wonyoung Jo, Taejoon Won, Abdel Daoud, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 13
Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies
Florian Moik, Jakob M. Riedl, Cornelia Englisch, et al.
Hämostaseologie (2024) Vol. 44, Iss. 01, pp. 040-048
Open Access | Times Cited: 11
Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors
Tamás G. Gergely, Zsófia D. Drobni, Nabil V. Sayour, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 9
Immune checkpoint inhibitors in cancer: the increased risk of atherosclerotic cardiovascular disease events and progression of coronary artery calcium
Bingxin Gong, Yusheng Guo, Yi Li, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 8
Uncovering atherosclerotic cardiovascular disease by PET imaging
Alexander Maier, Abraham J. P. Teunissen, Sheqouia A. Nauta, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 9, pp. 632-651
Closed Access | Times Cited: 8
Cardiovascular Considerations After Cancer Therapy
Anne Blaes, Anju Nohria, Saro H. Armenian, et al.
JACC CardioOncology (2025) Vol. 7, Iss. 1, pp. 1-19
Open Access | Times Cited: 1
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Emanuel Raschi, Simone Rossi, Andrea De Giglio, et al.
Drug Safety (2023) Vol. 46, Iss. 9, pp. 819-833
Open Access | Times Cited: 18
Adverse myocardial and vascular side effects of immune checkpoint inhibitors: a prospective multimodal cardiovascular assessment
Mariana Mirabel, Assié Eslami, Constance Thibault, et al.
Clinical Research in Cardiology (2024) Vol. 113, Iss. 8, pp. 1263-1273
Closed Access | Times Cited: 6
The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations
Cho‐Han Chiang, Cho‐Hung Chiang, Kevin Sheng‐Kai, et al.
Japanese Journal of Clinical Oncology (2022) Vol. 52, Iss. 12, pp. 1389-1398
Open Access | Times Cited: 23
Cancer Therapy-Associated Pulmonary Hypertension and Right Ventricular Dysfunction: Etiologies and Prognostic Implications
Orly Leiva, William Beaty, Steven Soo, et al.
Reviews in Cardiovascular Medicine (2024) Vol. 25, Iss. 3, pp. 87-87
Open Access | Times Cited: 5
Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall
Linda Piras, Michela Zuccanti, Paola Russo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2502-2502
Open Access | Times Cited: 4
Fluorescent probe-mediated labeling and real-time tracking of lipid droplet dynamics in foam cells formation
Jiandong Liu, Xingfang Wang, Jingyi Yu, et al.
Sensors and Actuators B Chemical (2024) Vol. 414, pp. 135942-135942
Closed Access | Times Cited: 4
Anticancer Chemotherapy-Induced Atherosclerotic Cardiovascular Disease: A Comprehensive Review
Juan S. Izquierdo‐Condoy, Marlon Arias-Intriago, Daniel Cardona, et al.
Life (2025) Vol. 15, Iss. 2, pp. 245-245
Open Access
Immune checkpoint inhibitors: Unraveling atherosclerotic cardiovascular risk.
Rhys Gray, Charlotte Manisty, Richard K. Cheng, et al.
Atherosclerosis (2025) Vol. 403, pp. 119147-119147
Closed Access
Cardiovascular toxicity induced by immunotherapy in non-small cell lung cancer: a systematic review and meta-analysis of observational studies
Josep Sabaté-Ortega, Eduard Teixidor-Vilà, Èlia Sais, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Immune checkpoint inhibitors and myocardial infarction
Vencel Juhász, Giselle Alexandra Suero-Abreu, Tomas G. Neilan
Journal of Thrombosis and Thrombolysis (2025)
Closed Access
Page 1 - Next Page

Scroll to top